Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.

Abstract

We report on the case of a patient with a diagnosis of a HER2-overexpressing metastatic breast cancer which was refractory to a combination of a Raf kinase inhibitor and docetaxel, but highly sensitive to trastuzumab, a HER2-targeted monoclonal antibody. Interestingly, there was no evidence of Ras-Raf-MAPK or PI3K-Akt pathways activation.

• Authors: M S Mano, A Awada, A Minisini, V Durbecq, A Di Leo, M Piccart
• Journal: Breast (Edinburgh, Scotland) (Breast) Vol. 13 Issue 4 Pg. 347-9 (Aug 2004) ISSN: 0960-9776 [Print] Netherlands
• PMID: 15325672 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Phosphatidylinositol 3-Kinases
• Receptor, ErbB-2
• raf Kinases
• Mitogen-Activated Protein Kinase Kinases
• Trastuzumab

Topics

• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents (therapeutic use)
• Breast Neoplasms (drug therapy, genetics, immunology)
• Drug Resistance, Neoplasm
• Female
• Genes, ras
• Humans
• Middle Aged
• Mitogen-Activated Protein Kinase Kinases
• Phosphatidylinositol 3-Kinases
• Receptor, ErbB-2 (genetics)
• Trastuzumab
• Treatment Outcome
• raf Kinases